GlassScriptPhysician profile
Sergio Zamora
NPI 1467412189
$2,887.18
in general payments reported to CMS, 2019-2025
25 companies · $1,766 in 2025
The $1,766 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $401 · 2021: $59.46 · 2022: $127 · 2023: $40.47 · 2024: $139 · 2025: $1,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085 · Travel and Lodging: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.96 |
| Travel and Lodging | $859.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $953.10 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Vaporox, INC. | $589.97 | 2025 | |
| Tepha INC | $253.18 | 2020 | |
| Organogenesis INC. | $249.09 | 2019-2025 | Puraply Wound Matrix |
| Smith+Nephew, INC. | $130.11 | 2020-2025 | Collagenase Santyl, Regranex |
| Janssen Pharmaceuticals, INC | $100.16 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $78.32 | 2019 | |
| Merck Sharp & Dohme LLC | $64.48 | 2019-2023 | Verquvo, Steglatro |
| Mimedx Group, INC. | $63.24 | 2025 | |
| Pfizer INC. | $42.16 | 2020-2025 | |
| Novo Nordisk INC | $40.79 | 2020-2024 | Rybelsus |
| Otsuka America Pharmaceutical, INC. | $38.96 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $30.50 | 2019-2022 | |
| Inspire Medical Systems, INC. | $28.62 | 2025 | Inspire |
| Misonix INC | $25.00 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.70 | 2019 | |
| Wright Medical Technology, INC. | $23.87 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $23.72 | 2019 | |
| Dexcom, INC. | $20.79 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $20.74 | 2023 | Cologuard Collection Kit |
| Tandem Diabetes Care, INC. | $20.62 | 2022 | |
| Sumitomo Pharma America, INC. | $18.55 | 2025 | Gemtesa |
| Lilly USA, LLC | $18.28 | 2025 | Mounjaro, Zepbound |
| Tactile Systems Technology INC | $17.01 | 2022 | |
| Glaxosmithkline, LLC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Zamora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.